Creating RNA nanoparticles to enhance gene expression in solid tumors
Development and characterization of self-amplifying RNA Lipid Nanoparticles for potent and multiplex gene expression in solid tumors
This study is testing a new way to deliver gene therapy directly to solid tumors to make cancer treatments like chemotherapy and immunotherapy work better, so patients might have a more effective and personalized option for fighting their cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10998606 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to deliver gene therapy directly to solid tumors, which are a major challenge in cancer treatment. The approach uses self-amplifying RNA combined with lipid nanoparticles to provide a sustained and effective delivery of multiple therapeutic agents. By targeting the tumor directly, this method aims to improve the effectiveness of existing treatments like chemotherapy and immunotherapy. Patients may benefit from a more potent and tailored treatment option that could enhance tumor clearance.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with solid tumors who are seeking innovative treatment options.
Not a fit: Patients with non-solid tumors or those who are not eligible for gene therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for solid tumors, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown promise with similar gene delivery methods, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Boston University (Charles River Campus) — Boston, United States (Active)
Researchers
- Principal investigator: Nambiar, Arun Kannoth — Boston University (Charles River Campus)
- Study coordinator: Nambiar, Arun Kannoth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.